IP Library Granted Patent US 10,064,896
Granted Patent B2
US 10,064,896 · App. 14/334,318 · Granted Sep 4, 2018

Spinal disc regenerative composition and method of manufacture and use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,896
App. No.
14/334,318
Granted
Sep 4, 2018
Kind
B2
Abstract

The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( 6 ) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material ( 10 ) that is dry and can be stored at room temperature for long periods of time. This powder ( 10 ) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture ( 20 ).

Claims (35)

1. An aqueous spinal disc regenerative composition suitable for injection, wherein the aqueous composition comprises:

a hydrated composition comprising freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of:

(i) providing normal human cadaveric intervertebral discs;

(ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs;

(iii) drying the nucleus pulposus;

(iv) micronizing the dried nucleus pulposus by pulverizing in a cryomill at a low temperature into particles sized less than 400 microns;

(v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv); and then

(vi) mixing the freeze-dried micronized nucleus pulposus with the fluid thereby producing the hydrated composition.

2. The aqueous spinal disc regenerative composition of claim 1 wherein the freeze-dried micronized nucleus pulposus provided for mixing in step (vi) is in the form of a powder.

3. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized freeze-dried nucleus pulposus has proteoglycan molecules.

4. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized freeze-dried nucleus pulposus has been dried to less than 5% moisture content prior to being rehydrated.

5. The aqueous spinal disc regenerative composition of claim 1 wherein the aqueous composition further comprises one or more of the following: stem cells, micronized amnion, platelet-rich plasma, growth factors, genetically altered cells that produce glycosaminoglycans, collagen Type 1 and glucose.

6. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized material of dried nucleus pulposus has water absorbed by the proteoglycan molecules depleted from the freeze-dried nucleus pulposus.

7. An aqueous spinal disc regenerative composition suitable for injection, wherein the aqueous composition comprises:

a hydrated composition comprising freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of:

(i) providing normal human cadaveric intervertebral discs;

(ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs;

(iii) drying the nucleus pulposus;

(iv) micronizing the dried nucleus pulposus by pulverizing in a cryomill at a low temperature into particles sized less than 400 microns;

(v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv);

(vi) mixing the freeze-dried micronized nucleus pulposus with the fluid thereby producing the hydrated composition;

wherein the freeze-dried micronized nucleus pulposus provided for mixing in step (vi) is in the form of a powder; and

mixing one or more of stem cells that are derived from marrow, fat, blood or interspinous ligaments; micronized amnion; platelet-rich plasma; and/or growth factors encapsulated in pharmacologically active microspheres, with the powdered freeze-dried micronized nucleus pulposus prior to step (vi), or with the hydrated composition after step (vi).

8. The composition of claim 1 wherein the normal human cadaveric intervertebral discs are intervertebral discs aseptically recovered from cadaveric spine segments from T9 to LS.

9. A composition consisting of:

(a) a syringe or injectable device which is capable of being inserted into a damaged disc to be treated; and

(b) a hydrated composition consisting of freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of:

(i) providing normal human cadaveric intervertebral discs;

(ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs;

(iii) drying the nucleus pulposus;

(iv) micronizing the dried nucleus pulposus by placing the dried material in a cryomill at low temperature and pulverizing the dried nucleus pulposus into particles sized less than 400 microns into a powder;

(v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv); and then

(vi) mixing the freeze-dried micronized nucleus pulposus with the fluid, thereby producing the hydrated composition and mixing one or more of stem cells that are derived from marrow, fat, blood or interspinous ligaments; micronized amnion; platelet-rich plasma; and/or growth factors encapsulated in pharmacologically active microspheres, with the powdered freeze-dried micronized nucleus pulposus prior to step (vi), or with the hydrated composition after step (vi);

wherein the (b) hydrated composition with one or more stem cells is contained within the (a) syringe or injectable device; and

wherein the (b) hydrated composition has a viscosity which permits it to flow through a cannula.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Aug 29, 2022
From: BANKUNITED, N.A.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 061333/0853 →
SECURITY INTEREST Recorded Aug 4, 2022
From: VIVEX BIOLOGICS GROUP, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 061084/0607 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2019
From: HERITAGE BANK OF COMMERCE
To: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
Reel/Frame 051282/0653 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 11, 2019
From: VIVEX BIOLOGICS GROUP, INC.
To: BANKUNITED, N.A.
Reel/Frame 051260/0064 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOLOGICS, INC.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 050079/0225 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOMEDICAL, INC.
To: VIVEX BIOLOGICS, INC.
Reel/Frame 050079/0179 →
SECURITY INTEREST Recorded Mar 19, 2019
From: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC.; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 048629/0691 →
SECURITY INTEREST Recorded Feb 22, 2017
From: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC.; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 041782/0452 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2014
From: TEMPLE, HARRY THOMAS
To: VIVEX BIOMEDICAL, INC.
Reel/Frame 033336/0852 →
Cited By (1)
US 12,667,594